Gallamine
Flaxedil (gallamine) is a small molecule pharmaceutical. Gallamine was first approved as Flaxedil on 1982-01-01. It is known to target muscarinic acetylcholine receptor M2 and acetylcholine receptor subunit alpha.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gallamine triethiodide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FLAXEDIL | Davis & Geck | N-007842 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
94 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 2 | 1 | 18 | 10 | 6 | 37 |
| Dementia | D003704 | F03 | — | — | 10 | 2 | 4 | 16 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 5 | 3 | 3 | — | 10 |
| Psychotic disorders | D011618 | F20.81 | — | 1 | 1 | 3 | — | 5 | |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | 1 | 2 | 1 | 4 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | 1 | 1 | 3 |
| Depression | D003863 | F33.9 | — | — | 1 | 1 | — | 2 | |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | 1 | — | 1 |
| Tic disorders | D013981 | F95 | — | — | — | 1 | — | 1 | |
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vascular dementia | D015140 | F01 | — | 1 | 3 | — | 1 | 4 | |
| Lewy body disease | D020961 | EFO_0006792 | G31.83 | — | — | 1 | — | 1 | 2 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | — | 2 | — | — | 2 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | 2 | — | — | 2 |
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Vascular ring | D000073872 | Q25.45 | — | 1 | 1 | — | — | 1 | |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | 1 | — | — | 1 |
| Nervous system diseases | D009422 | G00-G99 | — | — | 1 | — | — | 1 | |
| Cognition disorders | D003072 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | F17 | — | 2 | — | — | 1 | 3 | |
| Cocaine-related disorders | D019970 | F14 | — | 1 | — | — | 1 | 2 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | — | 1 |
| Aids dementia complex | D015526 | EFO_0002608 | — | 1 | — | — | — | 1 | |
| Traumatic brain injuries | D000070642 | S06 | — | 1 | — | — | — | 1 | |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 1 | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | G31.84 | — | 1 | — | — | — | 1 | |
| Frontotemporal dementia | D057180 | G31.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Insulin resistance | D007333 | EFO_0002614 | 1 | — | — | — | — | 1 | |
| Oxidative stress | D018384 | EFO_1001905 | 1 | — | — | — | — | 1 | |
| Smoking | D012907 | EFO_0003768 | F17 | 1 | — | — | — | — | 1 |
| Fasting | D005215 | EFO_0002756 | 1 | — | — | — | — | 1 | |
| Postural orthostatic tachycardia syndrome | D054972 | G90.A | 1 | — | — | — | — | 1 | |
| Memory | D008568 | 1 | — | — | — | — | 1 | ||
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aphasia | D001037 | HP_0002381 | R47.01 | — | — | — | — | 1 | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GALLAMINE |
| INN | gallamine triethiodide |
| Description | Gallamine triethiodide (Flaxedil) is a non-depolarising muscle relaxant. It acts by combining with the cholinergic receptor sites in muscle and competitively blocking the transmitter action of acetylcholine. Gallamine is a non-depolarising type of blocker as it binds to the acetylcholine receptor but does not have the biological activity of acetyl choline. Gallamine triethiodide has a parasympatholytic effect on the cardiac vagus nerve, which causes tachycardia and occasionally hypertension. Very high doses cause histamine release.[citation needed]
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC |
Identifiers
| PDB | — |
| CAS-ID | 153-76-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL360055 |
| ChEBI ID | — |
| PubChem CID | 6172 |
| DrugBank | DB00483 |
| UNII ID | Q3254X40X2 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CHRM2
CHRM2
CHRNA1
CHRNA1
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,227 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,081 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more